SGK3 is associated with estrogen receptor expression in breast cancer

[1]  Ji Luo,et al.  A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.

[2]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[3]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[4]  Shiuan Chen,et al.  SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. , 2011, Molecular endocrinology.

[5]  Jorge S. Reis-Filho,et al.  Molecular Profiling: Moving Away from Tumor Philately , 2010, Science Translational Medicine.

[6]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[8]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[9]  F. Miller,et al.  Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: Biomarkers of progression , 2009, International journal of cancer.

[10]  J. Qin,et al.  Identification of Flightless-I as a Substrate of the Cytokine-independent Survival Kinase CISK* , 2009, Journal of Biological Chemistry.

[11]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[12]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[13]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[14]  Jun Qin,et al.  Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells , 2008, Nature Cell Biology.

[15]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[16]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[17]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[18]  C. Creighton,et al.  A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors , 2007, Oncogene.

[19]  W. Muller,et al.  The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer , 2007, Oncogene.

[20]  C. Arteaga,et al.  Expression of active Akt protects against tamoxifen‐induced apoptosis in MCF‐7 Cells , 2006, IUBMB life.

[21]  G. Mills,et al.  A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners , 2006, Proceedings of the National Academy of Sciences.

[22]  E. Tokunaga,et al.  Activation of PI3K/Akt signaling and hormone resistance in breast cancer , 2006, Breast cancer.

[23]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[24]  Arul M Chinnaiyan,et al.  Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors , 2006, Genome Biology.

[25]  E. Tokunaga,et al.  The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. , 2006, European journal of cancer.

[26]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[27]  H. Loh,et al.  Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[28]  J. Bartlett,et al.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.

[29]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[30]  Z. Winters,et al.  Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. , 2005, European journal of cancer.

[31]  R. Dumitrescu,et al.  Understanding breast cancer risk ‐ where do we stand in 2005? , 2005, Journal of cellular and molecular medicine.

[32]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[33]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[34]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[35]  B. Payrastre,et al.  Phosphoinositide signaling disorders in human diseases , 2003, FEBS letters.

[36]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Mak,et al.  Dysregulated PTEN‐PKB and negative receptor status in human breast cancer , 2003, International journal of cancer.

[38]  Olle Stål,et al.  Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.

[39]  Motoo Nagane,et al.  Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. , 2002, Cancer research.

[40]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Jun Xu,et al.  Regulation of cytokine-independent survival kinase (CISK) by the Phox homology domain and phosphoinositides , 2001, The Journal of cell biology.

[43]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[44]  Dan Liu,et al.  Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival , 2000, Current Biology.

[45]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[46]  Mariano Provencio,et al.  Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype , 1999, Breast Cancer Research and Treatment.

[47]  L. Mulligan,et al.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.

[48]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[49]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[50]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[51]  C. Thompson,et al.  Apoptosis Meets Signal Transduction: Elimination of a BAD Influence , 1996, Cell.

[52]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[53]  F. Waldman,et al.  Patterns of epidermal growth factor receptor amplification in malignant gliomas. , 1996, The American journal of pathology.

[54]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[55]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[56]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[57]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[58]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[59]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.

[60]  D. Alessi,et al.  New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen. , 2009, The Biochemical journal.

[61]  Dan Liu,et al.  ERM-mediated genetic screens in mammalian cells. , 2008, Methods in enzymology.

[62]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[63]  D. Parkin.  International variation , 2004, Oncogene.

[64]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[65]  D. Haber,et al.  Hereditary breast cancer. , 1998, Annual review of medicine.

[66]  M. Stratton,et al.  The genetics of breast cancer susceptibility. , 1998, Annual review of genetics.